In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Conatus Pharmaceuticals Inc.. Trade Record

NASDAQ:CNAT Conatus Pharmaceuticals Inc. stock gains 31.89% Exit Jun 21, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart CNAT May 30, 2018, priceSeries
About Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. The company was founded in 2005 and is headquartered in San Diego, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
96.43
Entry Date
May 30, 2018
Entry Price
3.83
Sell Date
Jun 21, 2018
Sell Price
5.05
Net Gain
31.89%
Hold Time
16 Trading Days